Venture report: Torl doubles its series B funding in Deep Track-led B2

At least two companies raised $100 million-plus venture rounds in the past week, while a third announced its launch after a recent raise of that size.

Torl BioTherapeutics LLC raised an oversubscribed $158 million series B2 round, doubling its initial series B raised of $158 million last year. Deep Track Capital led the B2 round, with participation by RA Capital Management, Perceptive Advisors, Avidity Partners and Goldman Sachs, while Goldman Sachs was the lead investor in the B. Torl is one of six investments Goldman Sachs has made since developing a life science strategy in 2022. ...